arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Summit Therapeutics Inc.

SMMT
$14.18 ▼ -2.00 (-12.36%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Summit Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $11.0B
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC None
FCF / Share $-0.18 ↘
Trailing P/E —
Price / Book 17.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-189.42M
↓ -201.1% —
FCF / Share Free cash flow per share
$-0.18
↓ -15.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
4
Cash Quality ↓
32

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 9 years · 31 quarters